Wells Fargo’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-180,066
| Closed | -$71.6K | – | 7859 |
|
|
2023
Q3 | $71.6K | Sell |
180,066
-20,009
| -10% | -$9.86K | ﹤0.01% | 4973 |
|
|
2023
Q2 | $138K | Buy |
200,075
+9
| +0% | +$58 | ﹤0.01% | 4819 |
|
|
2023
Q1 | $1.58M | Buy |
200,066
+9,001
| +5% | +$31.3K | ﹤0.01% | 3055 |
|
|
2022
Q4 | $172K | Sell |
191,065
-8,998
| -4% | -$9.21K | ﹤0.01% | 4261 |
|
|
2022
Q3 | $218K | Buy |
200,063
+6
| +0% | +$8 | ﹤0.01% | 4200 |
|
|
2022
Q2 | $246K | Buy |
200,057
+5
| +0% | +$7 | ﹤0.01% | 4169 |
|
|
2022
Q1 | $472K | Hold |
200,052
| – | – | ﹤0.01% | 4448 |
|
|
2021
Q4 | $620K | Sell |
200,052
-50,000
| -20% | -$166K | ﹤0.01% | 4493 |
|
|
2021
Q3 | $1.01M | Sell |
250,052
-204
| -0.1% | -$850 | ﹤0.01% | 4228 |
|
|
2021
Q2 | $1.21M | Sell |
250,256
-1,160
| -0.5% | -$5.2K | ﹤0.01% | 4079 |
|
|
2021
Q1 | $1.3M | Buy |
251,416
+49,086
| +24% | +$342K | ﹤0.01% | 4057 |
|
|
2020
Q4 | $1.35M | Buy |
202,330
+92,094
| +84% | +$754K | ﹤0.01% | 3794 |
|
|
2020
Q3 | $1.12M | Buy |
110,236
+108,476
| +6,163% | +$1.28M | ﹤0.01% | 3764 |
|
|
2020
Q2 | $22K | Buy |
1,760
+1,745
| +11,633% | +$24.4K | ﹤0.01% | 5682 |
|
|
2020
Q1 | $0 | Sell |
15
-52
| -78% | -$349 | ﹤0.01% | 7261 |
|
|
2019
Q4 | $0 | Buy |
+67
| New | +$426 | ﹤0.01% | 6980 |
|
|
2018
Q2 | – | Sell |
-373
| Closed | -$12K | – | 6721 |
|
|
2018
Q1 | $12K | Buy |
+373
| New | +$11.9K | ﹤0.01% | 5916 |
|
|
2017
Q4 | – | Sell |
-1,333
| Closed | -$28K | – | 6643 |
|
|
2017
Q3 | $28K | Buy |
+1,333
| New | +$24.7K | ﹤0.01% | 5631 |
|
Other funds holding BLPH
Wells Fargo's BLPH Position: Q4 2023 in Review
Wells Fargo sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2023, closing a stake of 180,066 shares — an estimated $71.6K sold.
Wells Fargo first reported a position in BLPH in Q3 2017 and held it in 18 quarters. The position peaked at $1.58M in Q1 2023. 2 funds tracked by Wall St. Rank hold BLPH as of Q4 2023.
- Wells Fargo reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
- Wells Fargo sold 180,066 Bellerophon Therapeutics, Inc. shares in Q4 2023, an estimated $71.6K.
- Wells Fargo first reported a position in Bellerophon Therapeutics, Inc. in Q3 2017 and held it in 18 quarters.
- Wells Fargo's Bellerophon Therapeutics, Inc. position peaked at $1.58M in Q1 2023.
- 2 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2023.
Based on Wells Fargo's 13F filing for Q4 2023, filed 9 Feb 2024.